OvaScience (OVAS) Misses Q1 EPS by 8c

OvaScience (NASDAQ: OVAS) reported Q1 EPS of ($0.80), $0.08 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $146 thousand versus the consensus estimate of $110 thousand.

"OvaScience is currently focused on building our operational platform to support the expansion of the AUGMENT treatment. We are focusing our AUGMENT commercial efforts to target Canada and Japan as our initial, primary commercial markets,” said Michelle Dipp, M.D., Ph.D., Executive Chair and Chief Executive Officer of OvaScience. “We remain committed to building a pipeline of promising fertility treatments and continue to make progress in developing our OvaPrime and OvaTure programs. Over the coming months, we look forward to presenting validating data on our science at upcoming medical meetings and industry conferences. In addition, by year-end, we expect to update you on our path forward for OvaPrime.”

For earnings history and earnings-related data on OvaScience (OVAS) click here.

You May Also Be Interested In

• Morgan Stanley continues to recommend exposure to the broadening theme
• Rocket Lab to acquire Iridium in $8 billion cash-and-stock deal
• Lam Research (LRCX) PT Raised to $500 at Cantor Fitzgerald: Gaining Most Share in Group